In an ambitious scheme to develop a pipeline of drug therapies targeting hearing loss, Third Rock Ventures backed Decibel Therapeutics with a $52 million series A to advance "disruptive discoveries in the physiology of the ear," as characterized by Third Rock partner Kevin Starr, who serves as Decibel's chairman and interim CEO.